Uses of Desixen 360: - Iron overload - Transfusion dependent thalassemia Chronic iron overload. Hypersensitivity.

Antidote preparations

Deferasirox is an orally active chelator that is selective for iron (as Fe3+ ). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.

How to use Deferasirox: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Deferasirox is to be taken empty stomach. Administration: Should be taken on an empty stomach. Take on an empty stomach at least 30 min before meals preferably at the same time daily. Disperse tab completely by stirring in 100-200 mL of water/apple juice/orange juice until a fine susp is obtained; consume entire content. Rinse the glass w/ a little water/juice to resuspend any residue & drink remainder. Do not disperse tab in fizzy drinks/milk. Do not chew/ break/crush tab or swallow whole. Do not take w/ Al-containing antacids. Adult Dose: Transfusional Hemosiderosis Indicated for treatment of chronic iron overload caused by blood transfusion 20 mg/kg PO qDay; may increase by 5-10 mg increments based on serum ferritin; if not controlled on 30 mg/kg/day (ie, serum ferritin persistently >2500 mcg/L), may increase up to 40 mg/kg qDay Nontransfusion-Dependent Thalassemia Indicated for treatment of chronic iron overload caused by nontransfusion-dependent thalassemia syndromes and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (dw) and a serum ferritin >300 mcg/L 10 mg/kg PO qDay (calculate dose to nearest tablet size); if LIC >15 mg Fe/g dw after 4 weeks, consider increasing dose to 20 mg/kg/day Hepatic Impairment Mild (Child-Pugh A): No dose adjustment required Moderate (Child-Pugh B): Decrease initial dose by 50% Severe (Child-Pugh C): Avoid use Child Dose: Transfusional Hemosiderosis Indicated for treatment of chronic iron overload caused by blood transfusion <2 years: Safety and efficacy not established 20 mg/kg PO qDay; may increase by 5-10 mg increments based on serum ferritin; if not controlled on 30 mg/kg/day (ie, serum ferritin persistently >2500 mcg/L), may increase up to 40 mg/kg qDay Nontransfusion-Dependent Thalassemia Indicated for treatment of chronic iron overload caused by nontransfusion-dependent thalassemia syndromes and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (dw) and a serum ferritin >300 mcg/L <10 years: Safety and efficacy not established 10 mg/kg PO qDay (calculate dose to nearest tablet size); if LIC >15 mg Fe/g dw after 4 weeks, consider increasing dose to 20 mg/kg/day Renal Dose: Renal Impairment Baseline renal impairment CrCl 40-60 mL/min: Reduce starting dose by 50% Serum Cr >2 xULN or CrCl <40 mL/min: Do not use

Not to be used with aluminium-containing antacids as it may chelate aluminium.

Hypersensitivity.

Common - Nausea - Headache - Vomiting - Rash - Abdominal pain - Constipation - Itching - Increased liver enzymes - Abdominal distension - Diarrhea >10% Serum creatinine increase (dose related; 7-38%),Abdominal pain (21-28%),Nausea (11-23%),Vomiting (10-21%),Diarrhea (12-20%),Proteinuria (19%),Pyrexia (19%),Headache (16%),Cough (14%),Nasopharyngitis (13%),Pharyngolaryngeal pain (11%),Influenza (11%),Rash (8-11%) 1-10% Respiratory tract infection (10%),Bronchitis (9%),ALT increased (2-8%),Arthralgia, back pain (6-7%),Acute tonsillitis (6%),Rhinitis (6%),Fatigue (6%),Ear infection (5%),Transaminitis (4%),Urticaria (4%) <1% Anaphylaxis,Angioedema,Cytopenias, including agranulocytosis, neutropenia and thrombocytopenia; leukocytoclastic vasculitis Potentially Fatal: Acute renal failure, serious hypersensitivity reactions such as angioedema and anaphylaxis.

Pregnancy: No clinical data on exposed pregnancies are available for deferasirox. Studies in animals have shown some reproductive toxicity at maternally toxic doses. The potential risk for humans is unknown. As a precaution, it is recommended that Deferasirox not be used during pregnancy unless clearly necessary.Breast-feeding: In animal studies, Deferasirox was found to be rapidly and extensively secreted into maternal milk. No effect on the offspring was noted. It is not known if Deferasirox is secreted into human milk. Breast-feeding while taking Deferasirox is not recommended.

Precaution: Monitor renal function and CBC before starting treatment and regularly during treatment; may need to reduce dose or stop treatment if serum creatinine levels are persistently elevated. May increase LFTs. Perform audiological and ophthamological tests before starting treatment and yrly thereafter. Pregnancy. Lactation: not known whether excreted in breast milk, use caution

Single doses up to 40 mg/kg in normal subjects have been well tolerated. Acute signs of overdose may include nausea, vomiting, headache, and diarrhea. Overdose may be treated by induction of emesis or by gastric lavage, and by symptomatic treatment.

Store at 25° C. Protect from moisture.

Antidote preparations

Deferasirox is an orally active chelator that is selective for iron (as Fe3+ ion). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. It is used in the management of chronic iron overload.

Pregnancy There are no studies with use in pregnant women to inform drug-associated risks; administration of deferasirox to rats during pregnancy resulted in decreased offspring viability and an increase in renal anomalies in male offspring at doses that were about or less than recommended human dose on a mg/ m² basis; no fetal effects were noted in pregnant rabbits at doses equivalent to human recommended dose on a mg/ m² basis; drug should be used during pregnancy only if potential benefit justifies potential risk to fetus Contraception Counsel patients to use non-hormonal method(s) of contraception since drug can render hormonal contraceptives ineffective Lactation No data are available regarding presence of drug or its metabolites in human milk, effects on breastfed infant, or on milk production; drug and its metabolites is excreted in rat milk; because many drugs are excreted in human milk and because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue drug, taking into account importance of drug to mother